ASX:PMEPro Medicus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pro Medicus Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$26.98 +0.68 (+2.59 %) (As of 05/13/2020) Add Compare Share Today's RangeA$25.82Now: A$26.98▼A$27.1250-Day RangeA$26.98MA: A$26.98▼A$26.9852-Week RangeA$14.50Now: A$26.98▼A$38.39Volume285,954 shsAverage VolumeN/AMarket Capitalization$2.80 billionP/E Ratio127.87Dividend Yield0.40%BetaN/A ProfileAdvanced ChartCompetitorsDividendInsider TradesHeadlines Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions worldwide. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Pro Medicus. Previous Next 2.6 Community Rank Outperform VotesPro Medicus has received 21 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPro Medicus has received 19 “underperform” votes. (Add your “underperform” vote.)Community SentimentPro Medicus has received 52.50% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pro Medicus and other stocks. Vote “Outperform” if you believe PME will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PME will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.8 Dividend Strength Dividend YieldPro Medicus has a dividend yield of 0.40%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthPro Medicus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Pro Medicus is 47.39%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pro Medicus insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pro Medicus are expected to decrease by -100.00% in the coming year, from A$0.14 to A$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pro Medicus is 127.87, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Pro Medicus is 127.87, which means that it is trading at a more expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 43.42.Price to Book Value per Share RatioPro Medicus has a P/B Ratio of 53.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.69 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Health Information Services Sub-IndustryN/A SectorComputer and Technology Current SymbolASX:PME Previous Symbol CUSIPN/A CIKN/A Webwww.promed.com.au Phone61 3 9429 8800Debt Debt-to-Equity Ratio4.88 Current Ratio4.41 Quick Ratio4.34Price-To-Earnings Trailing P/E Ratio127.87 Forward P/E Ratio192.07 P/E GrowthN/A Sales & Book Value Annual Sales$54.08 million Price / Sales51.86 Cash FlowA$0.38 per share Price / Cash Flow71.76 Book ValueA$0.50 per share Price / Book53.53Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares103,947,000Market Cap$2.80 billion Next Earnings DateN/A OptionableNot Optionable Receive PME News and Ratings via Email Sign-up to receive the latest news and ratings for PME and its competitors with MarketBeat's FREE daily newsletter. Pro Medicus (ASX:PME) Frequently Asked Questions How has Pro Medicus' stock been impacted by COVID-19 (Coronavirus)? Pro Medicus' stock was trading at A$16.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PME stock has increased by 62.0% and is now trading at A$26.98. View which stocks have been most impacted by Coronavirus. How often does Pro Medicus pay dividends? What is the dividend yield for Pro Medicus? Pro Medicus declared a Interim dividend on Friday, February 14th. Stockholders of record on Friday, March 20th will be paid a dividend of 0.06 per share on Friday, March 20th. This represents a yield of 0.24%. The ex-dividend date of this dividend is Thursday, March 5th. This is an increase from Pro Medicus's previous Interim dividend of A$0.04. View Pro Medicus' dividend history. Has Pro Medicus been receiving favorable news coverage? Headlines about PME stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pro Medicus earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Pro Medicus. Who are some of Pro Medicus' key competitors? Some companies that are related to Pro Medicus include 10x Genomics (TXG), Schrodinger (SDGR), Compugroup Medical (COP), Craneware (CRW), Alcidion Group (ALC), Medadvisor (MDR), Resapp Health (RAP), Kneat.com (KSI), Mach7 Technologies (M7T), CogState (CGS), Sensyne Health (SENS), Vitalhub (VHI), Novita Healthcare (NHL), Reliq Health Technologies (RHT) and Induction Healthcare Group (INHC). View all competitors. What other stocks do shareholders of Pro Medicus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pro Medicus investors own include ImmuPharma (IMM), Blackmores (BKL), Bank of America (BAC), Boeing (BA), Accent Group (AX1), Axos Financial (AX), ARB (ARB), Appen (APX), Arista Networks (ANET) and Altium (ALU). Who are Pro Medicus' key executives? Pro Medicus' management team includes the following people: Dr. Sam Aaron Hupert, Co-Founder, Deputy Chairman, CEO & MDMr. Anthony Barry Hall, Co-Founder, Technology Director & Exec. DirectorDr. Malte Westerhoff, Global Chief Technology OfficerMr. Brad Levin, GM of North America & Global Head of MarketingMr. Danny Tauber, Gen. Mang. of Australia What is Pro Medicus' stock symbol? Pro Medicus trades on the ASX under the ticker symbol "PME." What is Pro Medicus' stock price today? One share of PME stock can currently be purchased for approximately A$26.98. How big of a company is Pro Medicus? Pro Medicus has a market capitalization of $2.80 billion and generates $54.08 million in revenue each year. What is Pro Medicus' official website? The official website for Pro Medicus is www.promed.com.au. How can I contact Pro Medicus? The company can be reached via phone at 61 3 9429 8800. This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
